Literature DB >> 11448559

Comparison of SeroMP IgA with four other commercial assays for serodiagnosis of Mycoplasma pneumoniae pneumonia.

T Watkins-Riedel1, G Stanek, F Daxboeck.   

Abstract

Acute phase serum samples from 23 patients with Mycoplasma pneumoniae pneumonia were examined for specific antibodies with microparticle agglutination (MAG)-assay, complement fixation (CF)-test, IgM-specific ELISA, and Immunocard-based IgM-EIA. A novel 3-h IgA-ELISA (SeroMP-IgA) was tested to assess its diagnostic value. For MAG, CF, IgM-ELISA, card-based IgM-EIA, and IgA-ELISA positive results were obtained in 87%, 87%, 91%, 87%, and 100%, respectively. Overall concordance was 78%. Specificity testing of 46 healthy blood donors revealed an optimal diagnostic cut-off range of 22-30 IgA-ELISA binding units (BU)/mL resulting in 91%-100% specificity and 100%-96% sensitivity for serologic diagnosis of acute M. pneumoniae infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11448559     DOI: 10.1016/s0732-8893(01)00250-4

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  12 in total

1.  Rapid detection of Mycoplasma pneumoniae IgM antibodies in pediatric patients using ImmunoCard Mycoplasma compared to conventional enzyme immunoassays.

Authors:  J J Dunn; A K Malan; J Evans; C M Litwin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-04-27       Impact factor: 3.267

2.  Juvenile spondyloarthropathies associated with Mycoplasma pneumoniae infection.

Authors:  Miroslav Harjacek; Jelena Ostojic; Oktavija Djakovic Rode
Journal:  Clin Rheumatol       Date:  2006-01-04       Impact factor: 2.980

3.  Evaluation of 12 commercial tests and the complement fixation test for Mycoplasma pneumoniae-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the "gold standard".

Authors:  Matthias F C Beersma; Kristien Dirven; Alje P van Dam; Kate E Templeton; Eric C J Claas; Herman Goossens
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

Review 4.  Mycoplasma pneumoniae from the Respiratory Tract and Beyond.

Authors:  Ken B Waites; Li Xiao; Yang Liu; Mitchell F Balish; T Prescott Atkinson
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

5.  Role of Serum Mycoplasma pneumoniae IgA, IgM, and IgG in the Diagnosis of Mycoplasma pneumoniae-Related Pneumonia in School-Age Children and Adolescents.

Authors:  Wei-Ju Lee; Eng-Yen Huang; Chih-Min Tsai; Kuang-Che Kuo; Yi-Chuan Huang; Kai-Sheng Hsieh; Chen-Kuang Niu; Hong-Ren Yu
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

6.  Microfluidic platform versus conventional real-time polymerase chain reaction for the detection of Mycoplasma pneumoniae in respiratory specimens.

Authors:  Elizabeth Wulff-Burchfield; Wiley A Schell; Allen E Eckhardt; Michael G Pollack; Zhishan Hua; Jeremy L Rouse; Vamsee K Pamula; Vijay Srinivasan; Jonathan L Benton; Barbara D Alexander; David A Wilfret; Monica Kraft; Charles B Cairns; John R Perfect; Thomas G Mitchell
Journal:  Diagn Microbiol Infect Dis       Date:  2010-03-12       Impact factor: 2.803

Review 7.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

8.  Analysis of eight commercial enzyme immunoassay tests for detection of antibodies to Mycoplasma pneumoniae in human serum.

Authors:  Deborah F Talkington; Susan Shott; Michael T Fallon; Stephanie B Schwartz; W Lanier Thacker
Journal:  Clin Diagn Lab Immunol       Date:  2004-09

9.  Persistently elevated IgA antibodies to Mycoplasma pneumoniae in patients with internal carotid artery stenosis.

Authors:  Florian Daxböck; Afshin Assadian; Thomas Watkins-Riedel; Ojan Assadian
Journal:  GMS Krankenhhyg Interdiszip       Date:  2011-12-15

Review 10.  A Compendium for Mycoplasma pneumoniae.

Authors:  Gretchen L Parrott; Takeshi Kinjo; Jiro Fujita
Journal:  Front Microbiol       Date:  2016-04-12       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.